Objectives: Ethambutol resistance has mostly been related to mutations in the embB gene. The objective of the present study was to characterize the embB gene in a collection of ethambutol-resistant and ethambutol-susceptible isolates of Mycobacterium tuberculosis complex (MTBC) from Barcelona, and to develop a DNA microarray for the rapid detection of embB mutations in our area.
Introduction
Ethambutol is a chemotherapeutic agent included in the range of frontline antituberculous (anti-TB) drugs. Current treatment guidelines highlight the role of ethambutol in the standard drug regimen against tuberculosis (TB), 1 especially in cases of confirmed or suspected resistance to other frontline anti-TB drugs such as isoniazid, rifampicin or pyrazinamide. Ethambutol acts by inhibiting arabinosyl transferases encoded by the embCAB operon. These enzymes are essential for the synthesis of arabinogalactan and lipoarabinomannan in the cell wall of the Mycobacterium tuberculosis complex (MTBC), and their inhibition leads to an accumulation of free mycolic acids and, ultimately, to cell death. 2, 3 In its last report on anti-TB drug resistance, the WHO reported, for 2008, a global resistance to ethambutol of 2.5% among new cases of TB and 10.3% among previously treated ones. 4 The main mechanism of resistance to ethambutol is the occurrence of chromosomal mutations in the embCAB operon, which implies an alteration of the ethambutol target. 5 Nucleotide changes in the ethambutol resistance-determining region (ERDR) of the embB gene are found in 50%-70% of ethambutol-resistant isolates of MTBC and other mycobacterial species. 6 The most frequent mutated position in the embB gene is codon 306 (embB306), with reports estimating that 30%-68% of the isolates presenting embB mutations have an embB306 substitution. 7 -10 Consequently, this target has recently been included in some commercial molecular systems for detecting ethambutol resistance. 11 Research suggests that embB306 mutations are also associated with multidrug-resistant (MDR; resistant to at least rifampicin and isoniazid) MTBC, 9, 12, 13 as well as resistance to other anti-TB drugs. 14 Mutations in embB codons other than 306, such as embB406 and embB497, have also been reported to be related to ethambutol resistance, 15, 16 and recent allelic exchange experiments have demonstrated the association between mutations in these codons and decreased in vitro susceptibility to ethambutol. 17 However, some studies have also found embB306 and embB406 substitutions to be present in ethambutol-susceptible isolates in certain geographical areas, 7,13,14,18 -22 thereby questioning the contribution of these mutations to ethambutol resistance, especially when this reaches high levels.
Given the diversity of codons involved in phenotypic resistance to ethambutol, the embB targets covered by commercially available molecular techniques 11 would appear to be insufficient. In recent years, microarrays, based on PCR and further hybridization with immobilized oligonucleotide probes, have emerged as a valuable system for detecting mutations associated with drugresistant TB. 23 -26 Hence, a low-density array may be a good tool for the rapid detection of ethambutol resistance in MTBC isolates.
The aims of the present study were as follows: (i) to determine the frequency of occurrence of the most common embB mutations in ethambutol-resistant isolates of MTBC recovered in the geographical area of Barcelona, and to clarify whether the most frequent substitutions in embB are also present in ethambutolsusceptible isolates; (ii) to correlate relevant embB mutations with the level of resistance to ethambutol, with the multidrug resistance pattern, and with epidemiological features such as international migration flows; and (iii) to design, develop and evaluate a low-cost, low-density array for the rapid detection of the main mutations in embB (LD-EMB array) that are related to ethambutol resistance in our area.
Materials and methods

Bacterial isolates
A total of 755 clinical isolates of MTBC, recovered in the geographical area of Barcelona between April 1994 and August 2010, were included in the study.
Among them, 53 were ethambutol resistant (all the ethambutol-resistant isolates detected during this period), 202 were ethambutol susceptible but resistant to at least one of the other frontline anti-TB drugs (51 were MDR, 64 were monoresistant to either isoniazid or pyrazinamide, and the remainder were resistant to isoniazid plus another first-line anti-TB drug, except for ethambutol and rifampicin) and 500 were pan-susceptible (susceptible to all frontline anti-TB drugs) isolates of MTBC. The 702 ethambutolsusceptible isolates were a representative collection during this studied period, obtained by selecting a set of isolates ranging from 30 to 50 per year. Each of the 755 MTBC isolates corresponded to a single patient presenting either pulmonary or extrapulmonary TB.
Phenotypic drug susceptibility
All MTBC isolates included in the study were tested for susceptibility against frontline anti-TB drugs using either: (i) the BACTEC 460 radiometric method Sequencing of the embB gene in ethambutol-resistant and ethambutol-susceptible isolates An internal fragment (codons 202-699; 1495 bp) of embB (Rv3795; 3297 bp; 1098 amino acids) for ethambutol-resistant isolates (n¼53) was amplified with primers embBRfor/embBRrev (Table 1) . Afterwards, ethambutol-susceptible isolates (n¼702) were embB internally sequenced in a shorter region (codons 202-528; 982 bp) than that for the ethambutolresistant isolate analysis, to focus only on the most important codons (306 and 406) using primers embBRfor/embBSrev ( Table 1) . Extraction of DNA from cultures consisted of a thermal disruption. 6 Amplification was carried out in a 50 mL volume containing 0.5 mL of each primer (25 mM), 0.6 mL of dNTPs (dATP, dCTP, dGTP and dTTP; 25 mM each), 10% (v/v) DMSO, 5 mL of the template DNA sample and 0.5 U of Taq Gold (Applied Biosystems, Warrington, UK). Thermal cycling reactions consisted of an initial denaturation (12 min at 948C) followed by 35 cycles of denaturation (1 min at 948C), annealing (1 min at 608C for embBRfor/embBRrev or at 668C for embBRfor/embBSrev) and extension (1 min 30 s at 728C), with a final extension of 10 min at 728C. Sequencing reactions were performed Moure et al.
externally (Macrogen, Korea) using embBRfor (10 mM), along with reverse primer embBRrev (10 mM) for ethambutol-resistant isolates or embBSrev (10 mM) for ethambutol-susceptible isolates. The nucleotide sequences obtained were compared with the embB wild-type sequence from reference strain H37Rv using the ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and Chromas Lite 2.1.1 (Technelysium, Australia) software packages.
Detection of embB mutations using the LD-EMB array
The LD-EMB array consisted of a transparent polymer support (50×50 mm) containing eight identical separated fields (eight samples). In these fields, there were 15 different capture probes spotted as duplicates. They were tagged at their 5 ′ end and ranged from 15 to 20 nucleotides. The design and distribution of the targets covered within the array was developed in-house (by the Mycobacteria Study Group in Barcelona), based on the results obtained in the sequencing analysis of ethambutol-resistant isolates included in the present study. In addition, a control probe (fungal origin) was spotted in three corners of the array in order to ensure the correct hybridization process. The prototype of the array was manufactured by Chipron GmbH (Berlin, Germany) ( Figure 1 ).
All 53 ethambutol-resistant isolates, as well as five of the pansusceptible isolates of MTBC, were analysed using this array. Genomic DNA from the clinical isolates was extracted using the InstaGene Matrix reagent (Bio-Rad, Hercules, CA, USA), following the manufacturer's instructions. Briefly, DNA amplification consisted of a duplex PCR covering codons 287-509. The reaction mixture comprised 12.5 mL of HotStarTaq Plus Mastermix Kit (Qiagen, Venlo, The Netherlands), 2 mL of the biotinylated primer mixture provided by the LD-EMB array kit, 2 mL of DMSO, 4.5 mL of sterile deionized water and 4 mL of the extracted DNA. Thermal cycling conditions were as follows: 5 min at 958C; 45 cycles of denaturation (30 s at 948C), annealing (45 s at 618C) and extension (45 s at 728C); and 5 min of final elongation at 728C. The primer sequences and the size of the resulting amplified fragments are shown in Table 1 . Afterwards, the PCR product (containing two amplified embB fragments) was mixed with a hybridization buffer and applied to the array (incubation for 35 min at 368C). The LD-EMB array was then washed in a low-salt buffer and labelled with a streptavidin-horseradish peroxidase solution for 5 min at room temperature. Finally, after a second washing step, the array was incubated in a stain solution at room temperature for 3 -5 min, until the precipitation of a dark substrate in the spots was clearly visible to the human eye. The resulting hybridization pattern was digitized (PrimeFilm 2700, Pacific Image Electronics Co., Ltd, Taiwan) and analysed using a software package (SlideReader 7, Chipron GmbH). The whole process (DNA amplification and hybridization) took ,4 h.
Genotyping
The ethambutol-resistant isolates were analysed by 24-locus mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) genotyping, as previously described, 27 in order to assess for possible epidemiological linkage among isolates.
Statistical analysis
The two groups of isolates containing the most important mutations were compared with regard to different features. To this end, two statistical variables were created: embB306 present/not present, and embB406 present/ not present. Qualitative comparisons were performed in SPSS, using either the x 2 test or Fisher's exact test, as appropriate. P values of ,0.05 were considered statistically significant.
Results
Characterization of the embB region in ethambutol-resistant and ethambutol-susceptible isolates
Among the 53 ethambutol-resistant isolates, 41 (77.4%) presented at least one amino acid substitution in the sequenced (Table 2 ) among isolates showing a mutation in embB. In two nonmutated isolates, the 24-locus MIRU-VNTR genotype could not be determined. Thus, when taking into account only unrelated isolates and one representative isolate of each cluster to determine the real occurrence of embB mutations in MTBC isolates circulating in our area, the number of ethambutol-resistant isolates was 37, of which 27 (72.9%) presented a nucleotide substitution within the sequenced embB fragment. Sixteen of these showed a mutation in codon 306 (16/27, 59.3%), seven a mutation in codon 406 (7/ 27, 25.9%) and one isolate (1/27, 3.7%) showed a double substitution (embB306 plus embB406); the remainder involved single mutations in codon 328, codon 378 and codon 497 (3/27, 11.1%) ( Table 2 ).
All 702 ethambutol-susceptible isolates showed a wild-type in the entire embB region that was sequenced.
Relationship between predominant mutations and the pattern of drug resistance embB mutations and phenotypic resistance to ethambutol (MIC)
All non-mutated, ethambutol-resistant isolates presented MICs of ethambutol of 7.5 mg/L or lower. In addition, values of MICs of ethambutol ≥15 mg/L (a high level of resistance) were correlated with the presence or absence of the two most important codons (variables embB306 present/not present and embB406 present/not present). The percentage of isolates showing high levels of resistance to ethambutol did not differ significantly according to whether an embB306 mutation was present (53.8%; 14/26) or not (73.3%; 11/15), whereas the difference was statistically significant in relation to whether an embB406 mutation was present (86.7%; 13/15) or not (46.2%; 12/26) (P ¼ 0.01). The MIC value for a double mutation in codons 306 and 406 was similar to that of isolates with single mutations. Finally, no association was found regarding the level of resistance to ethambutol and the specific amino acid substitution in each of the codons.
embB mutations and multidrug resistance
Thirty-seven of the 53 (69.8%) ethambutol-resistant isolates studied were also MDR. Among all the embB-mutated isolates, 82.9% (34/41) were MDR, whereas among non-mutated isolates the MDR percentage was 25% (3/12). Only 9.8% (4/41) of the embB-mutated isolates were ethambutol-monoresistant (all with a substitution in codon 306); in contrast, the percentage of ethambutol monoresistance was 58.3% (7/12) among nonmutated isolates. When taking into account the specific mutated codon in embB, the rate of multidrug resistance among isolates in which an embB306 mutation was present was 76.9% (20/26), versus 93.3% (14/15) among isolates without a mutation in this codon; this difference was not statistically significant. However, the percentage of multidrug resistance among isolates with at least one embB406 substitution was significantly higher than was found in the group of isolates without mutations in this codon (100% versus 73.1%, P¼ 0.035).
Relationship between predominant mutations and epidemiological features
The data regarding the country of origin of patients with embBmutated isolates revealed that 60% (9/15) of isolates without mutations in codon 306 belonged to patients who originated in a country other than Spain, this being the case for 46.2% (12/26) of isolates that showed an embB306 mutation. On the other hand, 66.7% (10/15) of isolates in which an embB406 mutation was present corresponded to foreign-born patients, who accounted for 42.3% (11/26) of the isolates without mutations in embB406. None of these differences was statistically significant.
When analysing the characteristics of the ethambutol-resistant isolates in our area according to the date of collection, we found no evidence of any temporal evolution, with regard to either the levels of ethambutol resistance (MIC) or the frequency of embB mutations.
All the calculations carried out to assess the relationship between predominant mutations and the MIC of ethambutol, multidrug resistance and epidemiological features were also performed taking into account only unrelated isolates and one representative isolate of each 24-locus MIRU-VNTR genotype cluster. This analysis revealed no significant differences for either of the two variables with respect to these features.
Detection of embB mutations using the LD-EMB array
Among the 53 ethambutol-resistant isolates studied, the LD-EMB array identified an embB306 substitution in 22 isolates, 11 isolates showed an embB406 mutation, 4 presented a double embB306 and embB406 substitution and one presented an embB497 mutation. Three isolates showed a lack of signal in all the probes spanning mutations, and they hybridized with all wild-type probes except for one (two isolates lacked hybridization with the wild-type embB328, and one lacked hybridization with the wild-type embB378). All five pan-susceptible isolates showed a wild-type pattern in the LD-EMB array (Figure 2) . The results obtained with the array were fully concordant with the sequencing data.
Discussion
The analysis of the ethambutol-resistant isolates of MTBC collected over a 16 year period in our area revealed that around threequarters of them presented a mutation in the ERDR of embB, this being consistent with previously published results. 5 These embBmutated isolates showed higher levels of resistance to ethambutol and a stronger relationship with polydrug resistance and multidrug resistance than did those isolates without mutations in embB but which still presented decreased susceptibility to ethambutol.
As reported elsewhere, 7 -10 substitutions in codon embB306 were the predominant mechanism associated with ethambutol resistance, since this target was involved in more than half of the resistant isolates studied. However, the frequency of mutations in codon 406 was also important in the present study. Moreover, the presence of mutations in embB406 was also shown to be related to multidrug resistance, as well as to a higher level of resistance to ethambutol (higher values of MIC). In addition, a trend 
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Characterization and rapid detection of embB mutations in Mycobacterium tuberculosis towards a relationship between mutation in embB406 and international migration was observed, although this did not reach statistical significance. This trend for isolates from foreign-born patients to present embB406 mutations is likely to be explained by the previously reported association between international migration flows and multidrug resistance 28 and the relationship between multidrug resistance and embB406 mutations identified in the present study. However, further studies are needed to confirm this hypothesis. The fact that the analysis of the relationship between these features and mutations in codons 306 and 406 did not show statistical significance when considering only unrelated embB-mutated isolates could be due to small size of this subsample. The analysis of the whole set of ethambutol-resistant isolates aimed to give some idea of the global prevalence of embB mutations among ethambutol-resistant clinical isolates in our area, whereas the analysis of unrelated isolates (and one representative isolate of each cluster) reflects the real occurrence of each embB mutation among circulating MTBC isolates in Barcelona.
It should also be noted that clustering was found only among embB-mutated isolates since all non-mutated isolates seemed to be unrelated according to 24-locus MIRU-VNTR genotyping, thereby supporting previously reported data and the possible epidemiological implications involved.
14 Among ethambutol-resistant isolates, especially those with substitutions in codon 306, the MIC values were not always correlated exclusively with a specific substitution. In some cases, the same substitution (e.g. 306 ATG ATC) conferred a different level of resistance to ethambutol, depending on the pattern of resistance of the isolate, being higher (up to 2-fold) if the isolate was MDR. Likewise, isolates belonging to the same cluster that presented the same mutation (e.g. 306 ATG GTG) and the same pattern of resistance sometimes presented different MIC values of ethambutol. These findings confirm the previously proposed hypothesis regarding the multifactorial nature of phenotypic resistance to ethambutol, and the idea that the acquisition of a mutation in the embB gene is a first step in developing resistance to ethambutol and other anti-TB drugs. 17 -20 Our analysis of codons embB306 and embB406 in a large set of ethambutol-susceptible isolates (of which 7.3% were MDR and 12.4% were polydrug resistant) revealed an absence of mutations in these positions, thereby demonstrating the significance of these codons with regard to ethambutol resistance. This finding contrasts with previous reports that questioned the role of codons embB306 and embB406 in resistance to ethambutol. This discrepancy may be due, in part, to heterogeneity in the methodologies used (e.g. drug susceptibility testing methods) or to the intrinsic molecular variability among isolates from diverse geographical regions.
According to the data shown by the analysis of the whole set of ethambutol-resistant isolates, which gives the idea of the global prevalence of the embB mutations in Barcelona, current molecular tests for detecting embB mutations, which are based solely on the embB306 target, would be insufficient in our setting. Indeed, when using the available commercial techniques for detecting genotypic resistance to ethambutol, .20% of ethambutol-resistant isolates with embB mutations would remain undetected in our area. The LD-EMB array proposed in the present study as a molecular method for detecting mutations related to ethambutol resistance included four additional targets, thereby increasing the spectrum of detection, mostly as a result of the inclusion of codon embB406. The system also contemplates a wider variety of possible substitutions in the case of embB306. The LD-EMB array described here demonstrated good effectiveness due to its excellent sensitivity and specificity. Furthermore, it was easy to handle, the results were obtained in one working day, and the cost ( 15 euros per sample) was lower than that of other commercially available techniques. Finally, as this is an array system, it offers enough flexibility to allow the inclusion of more or different targets of interest, depending on the epidemiological and molecular characteristics of each setting.
